| Assessment Status | Rapid review complete |
| HTA ID | 22052 |
| Drug | Eptinezumab |
| Brand | Vyepti® |
| Indication | For the prophylaxis of migraine in adults who have at least four migraine days per month |
| Assessment Process | |
| Rapid review commissioned | 20/07/2022 |
| Rapid review completed | 16/09/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of eptinezumab (Vyepti®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies* |
This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. June 2023
